Diagnostic Workup and Management of Multiple Myeloma

Initial Laboratory Assessment and Diagnostic Criteria

The National Comprehensive Cancer Network recommends a complete blood count with differential and peripheral blood smear evaluation, as well as a comprehensive chemistry panel, for the initial laboratory assessment of multiple myeloma 1, 2
Beta-2 microglobulin is an important prognostic marker and measure of tumor burden in multiple myeloma patients 1, 2
Serum protein electrophoresis and serum immunofixation electrophoresis are essential for the diagnosis of multiple myeloma 1, 3
Quantitative immunoglobulin levels and serum free light chain assay are also crucial for diagnosis, monitoring, and prognostication of multiple myeloma 1, 4
A 24-hour urine collection for total protein, urine protein electrophoresis, and urine immunofixation electrophoresis is necessary for accurate protein assessment 3
Anemia, defined as hemoglobin <10 g/dL or >2 g/dL below normal, is a common feature of multiple myeloma 3
Bone lesions, such as lytic lesions, severe osteopenia, or pathologic fractures, are also a characteristic of multiple myeloma 3

Bone marrow aspirate and biopsy are necessary for the diagnosis of multiple myeloma, with diagnosis confirmed when ≥10% clonal plasma cells are detected 3
CD138 staining and immunophenotyping are used to accurately determine plasma cell percentage and establish clonality 3
Cytogenetic studies, including FISH, are essential for identifying high-risk features such as del(17p), t(4;14), t(14;16), t(14;20), gain 1q, and p53 mutation 5
Skeletal survey, including spine, pelvis, skull, humeri, and femurs, is recommended for the initial assessment of multiple myeloma 3, 5
Advanced imaging, such as MRI and PET/CT scan, may be considered for suspected vertebral compression or extramedullary disease 1, 5

Regular assessment of monoclonal protein levels, at least every 3 months, is necessary for monitoring multiple myeloma patients 5
CBC, renal function, and calcium monitoring are also essential for follow-up care 5
Annual skeletal survey or as clinically indicated is recommended for monitoring bone disease 5
Bone marrow biopsy may be necessary based on clinical status 5
Serum free light chain monitoring may be considered for follow-up care 5